SS-31 · 10 mg

What is SS-31?

SS-31, also known in the research literature as elamipretide, is a synthetic tetrapeptide: a molecule made from four amino-acid residues. Researchers investigate its interactions with the inner mitochondrial membrane, where much of the cell’s ATP production takes place. ^[1]

Its scientific profile connects mitochondrial membrane biology with studies of muscle energetics and inherited mitochondrial disease. Findings range from isolated mitochondrial experiments and animal models to clinical trials in defined patient populations. ^{[1] [2] [3]}

How it works

A central research target is cardiolipin, a specialised lipid in the inner mitochondrial membrane. It helps organise the membrane environment used by proteins involved in respiration. Laboratory work found that SS-31 interacted with cardiolipin-containing membranes and influenced the relationship between cardiolipin and cytochrome c, an electron-transfer protein. ^[1]

In those experiments, SS-31 preserved electron-transfer activity while limiting the peroxidase activity of the cytochrome c–cardiolipin complex. Researchers also measured changes in respiration and ATP synthesis efficiency. These are specific experimental findings, not a guarantee that a person will feel more energetic. ^[1]

Main research areas

The same molecule can be studied for different questions. A result in a membrane preparation, an aged mouse or a rare-disease trial should be interpreted within that setting.

Clinical trial formulations and an authorised medicine are not automatically equivalent to an Everform research vial or pen.

What published findings show

Animal muscle research: Siegel and colleagues reported improved mitochondrial energy measurements and muscle-performance measures in aged mice. The work supports investigation of age-related mitochondrial dysfunction, but does not establish rejuvenation, longevity or exercise benefits in healthy people. ^[2]

Primary mitochondrial myopathy: MMPOWER-3 randomised 218 participants with genetically confirmed disease. Elamipretide did not significantly improve either of its primary outcomes—six-minute walking distance or total fatigue—compared with placebo over 24 weeks. This is an important limit on broad claims about energy and endurance. ^[3]

Barth syndrome: A 12-participant crossover trial did not meet its primary walking and symptom endpoints during the randomised phase. Improvements were reported during the subsequent open-label period, which lacked a concurrent placebo comparison. The different study phases should not be treated as equally strong evidence. ^[4]

Regulatory context: On 19 September 2025, the US FDA granted accelerated approval to Forzinity (elamipretide) to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. The decision relied on knee extensor strength findings, with a confirmatory trial required to verify clinical benefit. That specific approval does not apply to Everform’s research product or establish a general anti-ageing indication. ^[5]

Mechanistic promise, disease-specific trial findings and regulatory approval answer different questions. None establishes that this Everform SS-31 product improves general energy, athletic performance or lifespan.

The Everform product, at a glance

Everform Pharma is based in Da Nang, Vietnam. Select an available supply format using the product options above. Complimentary BAC water is included with every order.

Explore Your format, your way →

The full REF on the product should match the relevant documentation. The security sticker repeats the product identifier and should match the vial or pen; it is not a separate new ID. Follow the actual product label for storage conditions and expiry information.

Read identity, chromatographic purity and measured peptide content separately. A purity percentage alone does not confirm the amount per vial, and a matching molecular mass does not resolve every structural or stereochemical question.

Explore our label and COA guide →

Common questions